Trial Profile
A Probe Study of the Safety, Tolerability, and Immunogenicity of a 1-Dose Regimen of the MRKAd5 HIV-1 Gag Vaccine Versus the ALVAC-HIV (vCP205) Vaccine in Healthy Adults Who Previously Received a 3-Dose Regimen of MRKAd5, Ad5, or Placebo in Merck V520 Protocols 007 or 012.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs V 520 (Primary) ; HIV vaccine vCP205
- Indications HIV-1 infections
- Focus Adverse reactions
- Sponsors Merck & Co; Merck Sharp & Dohme
- 09 Jul 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 11 May 2009 New trial record